Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Relapse after HSCT 2021
Time to reveal our Top 6 most-viewed interviews of the year! 🎥🩸
1) The evolving treatment landscape for patients with #PolycythemiaVera - @MKremyanskaya
2) Dr Jason Westin discusses the ALPHA3 trial from ASCO 2025 - @Lymphoma_Doc
3) Outcomes with CAR-T therapy in autoimmune…
As the year comes to a close, we're looking back on our Top 10 most viewed video interviews of 2025, starting with 7th-10th place! 🎥🩸
7) Updates in the management of CMML: a case-based presentation - Daniel Wiseman (@OfficialUoM)
8) In vivo CAR T-cell therapy: benefits and…
In an interview from #ASH25, @Dr_AmerZeidan (@Yale) shares insights from a secondary analysis of the IMerge trial, which identified a correlation between treatment-emergent cytopenias and clinical response in patients with LR-MDS receiving imetelstat.
Watch here: 👉…
Want to hear results from the Phase III BRUIN-CLL-314 study comparing pirtobrutinib to ibrutinib in treatment-naïve and R/R CLL?
Watch our interview with Jennifer Woyach (@OSUCCC_James) from #ASH25 here:
🎥
#CLLsm #Leusm #Leukemia #CTSM #TrialUpdate…
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, shares results from the Phase III BRUIN-CLL-314 study ...
ow.ly
Couldn't make it to #ASH25?🩸
Lucky for you, we've got hundreds of expert interviews from the event on https://ow.ly/NOwN50XGJ0i, so that you can catch up on the latest updates and advances quickly and easily! 🎥😃
Click here to explore our exclusive coverage:
👉…
Relapse after HSCT 2021
Time to reveal our Top 6 most-viewed interviews of the year! 🎥🩸
1) The evolving treatment landscape for patients with #PolycythemiaVera - @MKremyanskaya
2) Dr Jason Westin discusses the ALPHA3 trial from ASCO 2025 - @Lymphoma_Doc
3) Outcomes with CAR-T therapy in autoimmune…
As the year comes to a close, we're looking back on our Top 10 most viewed video interviews of 2025, starting with 7th-10th place! 🎥🩸
7) Updates in the management of CMML: a case-based presentation - Daniel Wiseman (@OfficialUoM)
8) In vivo CAR T-cell therapy: benefits and…
In an interview from #ASH25, @Dr_AmerZeidan (@Yale) shares insights from a secondary analysis of the IMerge trial, which identified a correlation between treatment-emergent cytopenias and clinical response in patients with LR-MDS receiving imetelstat.
Watch here: 👉…
Want to hear results from the Phase III BRUIN-CLL-314 study comparing pirtobrutinib to ibrutinib in treatment-naïve and R/R CLL?
Watch our interview with Jennifer Woyach (@OSUCCC_James) from #ASH25 here:
🎥
#CLLsm #Leusm #Leukemia #CTSM #TrialUpdate…
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, shares results from the Phase III BRUIN-CLL-314 study ...
ow.ly
Couldn't make it to #ASH25?🩸
Lucky for you, we've got hundreds of expert interviews from the event on https://ow.ly/NOwN50XGJ0i, so that you can catch up on the latest updates and advances quickly and easily! 🎥😃
Click here to explore our exclusive coverage:
👉…
